comprehensive -WSS

comprehensive

author：explore 2025-09-30 22:28:39 - browse：9583

om DiLenge (CQ in grey suit ) Flagship Pioneering Cambridge with US Congressman Raja Krishnamoorthi of Illinois were talking together at the event. Biotech companies demonstrating their medicines and materials at a "tech fair" designed to showcase the need to compete with Chinese biotech held at Harvard Kennedy School in Cambridge. The growing US backlash against the perceived national security threat posed by China's rising biotech industry — Tom DiLenge of Flagship Pioneering (left) with U.S. Congressman Raja Krishnamoorthi of Illinois at a "tech fair" designed to showcase the need to compete with Chinese biotech held at Harvard Kennedy School in Cambridge, Mass. David L Ryan/The Boston Globe

CAMBRIDGE, Mass. — The increasingly adversarial relationship between the United States and China has raised national security concerns about Chinese penetration into key sectors of the U.S. economy, such as technology, manufacturing, and clean energy.

Now, some in Congress are raising alarms about China’s threat to another vital industry: biotechnology.

A bipartisan group of lawmakers visited Massachusetts this week to call attention to that threat and call for strengthening U.S. life sciences companies, protecting their technologies, and safeguarding Americans’ genetic data from a Chinese biotech industry with close ties to the authoritarian state.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Anavex keeps shifting the goalposts in its clinical trials

WSS

JPM: CVS says Medicare Advantage patients are impacting profits

The biotech scorecard for Q1: 17 stock

Anavex keeps shifting the goalposts in its clinical trials

J&J to buy cancer drug developer Ambrx Biopharma

The biotech scorecard for Q1: 17 stock

3 medical device trends to watch in 2024

explore

comprehensive

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

Morgan Health, with ambitious aims, wants you to know it’s still here

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A single drug, study failures leave Anavex with nothing but cash

After affirmative action ruling, medical educators look to 'holistic review'

American woman, child freed after being kidnapped in Haiti last month

State Dept. review finds Biden bears some blame for Afghanistan failures

Wegovy trial has doctors encouraged over new possibilities

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Feng Zhang, Grail founder join forces on new gene editing startup

hotspot

Maui's cultural, historic landmarks damaged in the devastating wildfires

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

U.K. sequencing study surfaces new findings about tumor DNA

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Why psychiatrists like me stop taking insurance

hotspot

hotspot

knowledge

focus